AGIO:NAS (USA) Also trade in: Germany

Agios Pharmaceuticals Inc

$ 56.47 0.5 (0.88%)
Volume: 200,534 Avg Vol (1m): 428,751
Market Cap $: 3.30 Bil Enterprise Value $: 2.72 Bil
P/E (TTM): 0.00 P/B: 4.79
Earnings Power Value -47.72
Net Current Asset Value 7.61
Tangible Book 11.81
Projected FCF -12.06
Median P/S Value 67.48
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 10/10

Current vs industry vs history
Cash-to-Debt No Debt
N/A
Equity-to-Asset 0.80
Interest Coverage No Debt
N/A
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 9.18
DISTRESS
GREY
SAFE
Beneish M-Score -1.19
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -543.44%
WACC 17.87%

Profitability & Growth : 2/10

Current vs industry vs history
Operating Margin % -384.03
Net Margin % -366.61
ROE % -49.26
ROA % -38.96
ROC (Joel Greenblatt) % -1495.01
3-Year Total Revenue Growth Rate 16.90
3-Year Total EBITDA Growth Rate -45.50
3-Year EPS w/o NRI Growth Rate -24.20

» AGIO's 30-Y Financials

Financials (Next Earnings Date: 2019-05-03)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:AGIO

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare OSTO:SOBI NAS:UTHR SZSE:000661 NAS:AVXS NAS:SRPT NAS:BPMC XKRX:128940 SZSE:002007 BOM:532523 HKSE:01548 XBRU:ABLX HKSE:01530 SHSE:600201 NAS:TECH NAS:FGEN SZSE:300347 NAS:AAAP LSE:BTG LSE:ABC TSE:4587
Traded in other countries 8AP.Germany
Address 88 Sidney Street, Cambridge, MA, USA, 02139
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

Ratios

Current vs industry vs history
PB Ratio 4.79
PS Ratio 34.56
EV-to-EBIT -7.50
EV-to-EBITDA -7.65
EV-to-Revenue 28.77
Current Ratio 6.56
Quick Ratio 6.55
Days Inventory 90.51
Days Sales Outstanding 40.38
Days Payable 4.00

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -15.60

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 4.79
Price-to-Median-PS-Value 0.84
Earnings Yield (Joel Greenblatt) % -13.36

More Statistics

Revenue (TTM) (Mil) $ 94.39
EPS (TTM) $ -6.03
Beta 2.55
Volatility % 49.76
52-Week Range $ 41.63 - 99.82
Shares Outstanding (Mil) 58.68

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y